A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation
| dc.citation.epage | 335 | pt_BR |
| dc.citation.issue | 4 | pt_BR |
| dc.citation.spage | 330 | pt_BR |
| dc.citation.volume | 9 | pt_BR |
| dc.creator | Atalla, Angelo | |
| dc.creator | Maiolino, Angelo | |
| dc.creator | Guimarães, Maria Angélica | |
| dc.creator | Guimarães, Antonio Carlos | |
| dc.creator | Nucci, Marcio | |
| dc.date.accessioned | 2019-02-22T12:04:00Z | |
| dc.date.available | 2019-02-18 | |
| dc.date.available | 2019-02-22T12:04:00Z | |
| dc.date.issued | 2005-08 | |
| dc.description.abstract | The reactivation of Herpes Simplex virus (HSV) occurs in 70% to 80% of patients submitted to autologous stem cell transplantation (ASCT); it increases the severity of chemotherapy-induced mucositis. Therefore, the use of acyclovir in ASCT patients is considered standard practice. However, the minimum dose needed to prevent reactivation is a matter of debate. We compared two doses of acyclovir in a non-randomized fashion in 59 patients submitted to ASCT: 32 patients received a dose of 125 mg/m2 IV every six hours and the subsequent 27 patients received a dose of 60 mg/m2 IV every six hours. Viral excretion was evaluated through weekly viral culture of oral swabs. Grade 4 mucositis was more frequent in Group 1 (p= 0.03). The reactivation rates in Groups 1 and 2 were 9% and 4%, respectively (p= 0.62, 95% confidence interval -7 - 18). Prophylaxis with reduced doses of intravenous acyclovir seems to be as effective as a higher dose in inhibiting HSV reactivation, with a significant reduction in cost. Prospective randomized studies are needed to confirm our conclusions. | pt_BR |
| dc.description.resumo | - | pt_BR |
| dc.identifier.doi | http://dx.doi.org/10.1590/S1413-86702005000400010 | pt_BR |
| dc.identifier.uri | https://repositorio.ufjf.br/handle/ufjf/9102 | |
| dc.language | eng | pt_BR |
| dc.publisher | - | pt_BR |
| dc.publisher.country | Brasil | pt_BR |
| dc.publisher.initials | - | pt_BR |
| dc.relation.ispartof | Brazilian Journal of Infectious Diseases | pt_BR |
| dc.rights | Acesso Aberto | pt_BR |
| dc.subject | Acyclovir | pt_BR |
| dc.subject | Prophylaxis | pt_BR |
| dc.subject | Stem cell transplantation | pt_BR |
| dc.subject.cnpq | - | pt_BR |
| dc.title | A non-randomized comparative study using different doses of acyclovir to prevent herpes simplex reactivation in patients submitted to autologous stem cell transplantation | pt_BR |
| dc.type | Artigo de Periódico | pt_BR |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- A non-randomized comparative study using different doses of acyclovir to prevent herpes.pdf
- Size:
- 34.38 KB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 2.15 KB
- Format:
- Item-specific license agreed upon to submission
- Description:
